cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.13060481
title: Supplementary Material for: Heterogeneity of Effect of Net Ultrafiltration Rate among Critically Ill Adults Receiving Continuous Renal Replacement Therapy

description: <b><i>Introduction:</i></b> In continuous renal replacement therapy (CRRT)-treated patients, a net ultrafiltration (NUF) rate &gt;1.75 mL/kg/h has been associated with increased mortality. However, there may be heterogeneity of effect of NUF rate on mortality, according to patient characteristics. <b><i>Methods:</i></b> To investigate the presence and impact of heterogeneity of effect, we performed a secondary analysis of the “Randomized Evaluation of Normal versus Augmented Level of Renal Replacement Therapy” (RENAL) trial. Exposure was NUF rate (weight-adjusted fluid volume removed per hour) stratified into tertiles (&lt;1.01 mL/kg/h; 1.01–1.75 mL/kg/h; or &gt;1.75 mL/kg/h). Primary outcome was 90-day mortality. Patients were clustered according to baseline characteristics. Heterogeneity of effect was assessed according to clusters and baseline edema and related to the additional impact of baseline cardiovascular Sequential Organ Failure Assessment (SOFA) score. We excluded patients with missing values for baseline weight and/or treatment duration. <b><i>Results:</i></b> We identified 2 clusters. The largest (cluster 1; <i>n</i> = 941) included more severely ill patients, with more sepsis, more edema, and more vasopressor therapy (all <i>p</i> &lt; 0.001). Compared to the middle tertile, the probability of harm was greater with the high tertile of NUF rate in patients in cluster 1 and in patients with baseline edema (probability of harm, cluster 1: 99.9%; edema: 99.1%). Moreover, higher baseline cardiovascular SOFA score also increased mortality risk with both high and low compared to middle NUF rates in cluster 1 patients and in patients with edema. <b><i>Conclusions:</i></b> In CRRT patients, both high and low NUF rates may be harmful, especially in those with edema, sepsis, and greater illness severity. Cardiovascular SOFA scores modulate this association. Additional studies are needed to test these hypotheses, and targeted trials of NUF rates based on risk stratification appear justified. <b><i>Trial Registration:</i></b> ClinicalTrials.gov identifier: NCT00221013.
DOI: 10.6084/m9.figshare.13060481.v1
title: Supplementary Material for: Heterogeneity of Effect of Net Ultrafiltration Rate among Critically Ill Adults Receiving Continuous Renal Replacement Therapy

description: <b><i>Introduction:</i></b> In continuous renal replacement therapy (CRRT)-treated patients, a net ultrafiltration (NUF) rate &gt;1.75 mL/kg/h has been associated with increased mortality. However, there may be heterogeneity of effect of NUF rate on mortality, according to patient characteristics. <b><i>Methods:</i></b> To investigate the presence and impact of heterogeneity of effect, we performed a secondary analysis of the “Randomized Evaluation of Normal versus Augmented Level of Renal Replacement Therapy” (RENAL) trial. Exposure was NUF rate (weight-adjusted fluid volume removed per hour) stratified into tertiles (&lt;1.01 mL/kg/h; 1.01–1.75 mL/kg/h; or &gt;1.75 mL/kg/h). Primary outcome was 90-day mortality. Patients were clustered according to baseline characteristics. Heterogeneity of effect was assessed according to clusters and baseline edema and related to the additional impact of baseline cardiovascular Sequential Organ Failure Assessment (SOFA) score. We excluded patients with missing values for baseline weight and/or treatment duration. <b><i>Results:</i></b> We identified 2 clusters. The largest (cluster 1; <i>n</i> = 941) included more severely ill patients, with more sepsis, more edema, and more vasopressor therapy (all <i>p</i> &lt; 0.001). Compared to the middle tertile, the probability of harm was greater with the high tertile of NUF rate in patients in cluster 1 and in patients with baseline edema (probability of harm, cluster 1: 99.9%; edema: 99.1%). Moreover, higher baseline cardiovascular SOFA score also increased mortality risk with both high and low compared to middle NUF rates in cluster 1 patients and in patients with edema. <b><i>Conclusions:</i></b> In CRRT patients, both high and low NUF rates may be harmful, especially in those with edema, sepsis, and greater illness severity. Cardiovascular SOFA scores modulate this association. Additional studies are needed to test these hypotheses, and targeted trials of NUF rates based on risk stratification appear justified. <b><i>Trial Registration:</i></b> ClinicalTrials.gov identifier: NCT00221013.
DOI: 10.6084/m9.figshare.13060313.v1
title: R14.7z

description: Smart meter data for the residence in SEIL-R dataset.
DOI: 10.6084/m9.figshare.13060334.v1
title: R15.7z

description: Smart meter data for the residence in SEIL-R dataset.
DOI: 10.6084/m9.figshare.13060292
title: R13.7z

description: Smart meter data for the residence in SEIL-R dataset.
DOI: 10.6084/m9.figshare.13060334
title: R15.7z

description: Smart meter data for the residence in SEIL-R dataset.
DOI: 10.6084/m9.figshare.13060292.v1
title: R13.7z

description: Smart meter data for the residence in SEIL-R dataset.
DOI: 10.6084/m9.figshare.13060274
title: R12.7z

description: Smart meter data for the residence in SEIL-R dataset.
DOI: 10.6084/m9.figshare.13060241.v1
title: R9.7z

description: Smart meter data for the residence in SEIL-R dataset.
DOI: 10.6084/m9.figshare.13060313
title: R14.7z

description: Smart meter data for the residence in SEIL-R dataset.
DOI: 10.6084/m9.figshare.13060178
title: R4.7z

description: Smart meter data for the residence in SEIL-R dataset.
DOI: 10.6084/m9.figshare.13060193
title: R6.7z

description: Smart meter data for the residence in SEIL-R dataset.
DOI: 10.6084/m9.figshare.13060226
title: R7.7z

description: Smart meter data for the residence in SEIL-R dataset.
DOI: 10.6084/m9.figshare.13060229
title: R8.7z

description: Smart meter data for the residence in SEIL-R dataset.
DOI: 10.6084/m9.figshare.13060178.v1
title: R4.7z

description: Smart meter data for the residence in SEIL-R dataset.
DOI: 10.6084/m9.figshare.13060274.v1
title: R12.7z

description: Smart meter data for the residence in SEIL-R dataset.
DOI: 10.6084/m9.figshare.13060364
title: R16.7z

description: Smart meter data for the residence in SEIL-R dataset.
DOI: 10.6084/m9.figshare.13060364.v1
title: R16.7z

description: Smart meter data for the residence in SEIL-R dataset.
DOI: 10.6084/m9.figshare.13060166.v1
title: R3.7z

description: Smart meter data for the residence in SEIL-R dataset.
DOI: 10.6084/m9.figshare.13059866
title: R1.7z

description: Smart meter data for the residence in SEIL-R dataset.
DOI: 10.6084/m9.figshare.13060166
title: R3.7z

description: Smart meter data for the residence in SEIL-R dataset.
DOI: 10.6084/m9.figshare.13059842.v1
title: R11.7z

description: Smart meter data for the residence in SEIL-R dataset.
DOI: 10.6084/m9.figshare.13059866.v1
title: R1.7z

description: Smart meter data for the residence in SEIL-R dataset.
DOI: 10.6084/m9.figshare.13060079.v1
title: R10.7z

description: Smart meter data for the residence in SEIL-R dataset.
DOI: 10.6084/m9.figshare.13059842
title: R11.7z

description: Smart meter data for the residence in SEIL-R dataset.
DOI: 10.6084/m9.figshare.13060079
title: R10.7z

description: Smart meter data for the residence in SEIL-R dataset.
DOI: 10.5281/zenodo.3833799
title: Short-chain cello-oligosaccharides: Intensification and scale-up of their enzymatic production and selective growth promotion among probiotic bacteria

description: We provide here the underlying data of the scientific publication "Short-chain cello-oligosaccharides: Intensification and scale-up of their enzymatic production and selective growth promotion among probiotic bacteria". Please find the abstract below: Short-chain cello-oligosaccharides (COS; degree of polymerization, DP≤6) are promising water-soluble dietary fibers. An efficient approach to their bottom-up synthesis is from sucrose and glucose using glycoside phosphorylases. Here, we show intensification and scale up (20 mL; gram scale) of COS production to 93 g/L product and in 82 mol % yield from sucrose (0.5 M). The COS were comprised of DP 3 (33 wt %), DP 4 (34 wt %), DP 5 (24 wt %) and DP 6 (9 wt %) and involved minimum loss (≤10 mol %) to insoluble fractions. After isolation (≥95% purity; ≥90% yield), the COS were examined for growth promotion of probiotic strains. Benchmarked against inulin, trans-galacto-oligosaccharides and cellobiose, COS showed up to 4.1-fold stimulation of cell density for <em>Clostridium butyricum</em>, <em>Lactococcus lactis</em> subsp.<em>lactis</em>, <em>Lactobacillus paracasei</em> subsp. <em>paracasei</em> and <em>Lb. rhamnosus</em> but were less efficient with <em>Bifidobacterium</em> sp. This study shows the COS as selectively functional carbohydrates with prebiotic potential and demonstrates their efficient enzymatic production.
DOI: 10.5281/zenodo.3833798
title: Short-chain cello-oligosaccharides: Intensification and scale-up of their enzymatic production and selective growth promotion among probiotic bacteria

description: We provide here the underlying data of the scientific publication "Short-chain cello-oligosaccharides: Intensification and scale-up of their enzymatic production and selective growth promotion among probiotic bacteria". Please find the abstract below: Short-chain cello-oligosaccharides (COS; degree of polymerization, DP≤6) are promising water-soluble dietary fibers. An efficient approach to their bottom-up synthesis is from sucrose and glucose using glycoside phosphorylases. Here, we show intensification and scale up (20 mL; gram scale) of COS production to 93 g/L product and in 82 mol % yield from sucrose (0.5 M). The COS were comprised of DP 3 (33 wt %), DP 4 (34 wt %), DP 5 (24 wt %) and DP 6 (9 wt %) and involved minimum loss (≤10 mol %) to insoluble fractions. After isolation (≥95% purity; ≥90% yield), the COS were examined for growth promotion of probiotic strains. Benchmarked against inulin, trans-galacto-oligosaccharides and cellobiose, COS showed up to 4.1-fold stimulation of cell density for <em>Clostridium butyricum</em>, <em>Lactococcus lactis</em> subsp.<em>lactis</em>, <em>Lactobacillus paracasei</em> subsp. <em>paracasei</em> and <em>Lb. rhamnosus</em> but were less efficient with <em>Bifidobacterium</em> sp. This study shows the COS as selectively functional carbohydrates with prebiotic potential and demonstrates their efficient enzymatic production.
DOI: 10.6084/m9.figshare.12894020
title: Coleorhiza-enforced seed dormancy: a novel mechanism to control germination in grasses - Raw Data

description: Raw data from the manuscript 'Coleorhiza-enforced seed dormancy: a novel mechanism to control germination in grasses<br>
DOI: 10.6084/m9.figshare.13060226.v1
title: R7.7z

description: Smart meter data for the residence in SEIL-R dataset.
DOI: 10.6084/m9.figshare.13060229.v1
title: R8.7z

description: Smart meter data for the residence in SEIL-R dataset.
DOI: 10.6084/m9.figshare.9816581
title: Annotated MAG files from the pig gut microbiome

description: <b>Folder: Dataset S1_MAGs_Prokka_ORFs</b>Contains 355 fasta files that represent MAGs reconstructed from the pig gut microbiome. Each MAG file contains predicted genes (amino acid sequences) as well as annotated gene function. <br><br><b>Folder:</b><b> Dataset S2_MAGs_MetaP_CAZy</b>Contains proteomic mapping information for each MAG, including the gene ID, gene annotation and label free quantification score for each detected protein. Additional CAZy.org annotation is also included.<br>
DOI: 10.6084/m9.figshare.12334586
title: 20200513 - betafunnorms familial hypercholesterolemia.csv

description: This dataset contains normalized DNA methylation data (betafunnorm) of patients with Familial Hypercholesterolemia (FH). The dataset consists of two groups of FH patients; those with a pathogenic variant in <i>LDLR</i> (FH1) and those without moleculary defects causing FH, but with LDL-C &gt; 6 mmol/L (FH4). All participants are male and not using any lipid lowering therapies.
DOI: 10.6084/m9.figshare.13060562
title: Supplementary Material for: The Efficacy and Safety of Topical β-Blockers in Treating Infantile Hemangiomas: A Meta-Analysis Including 11 Randomized Controlled Trials

description: <b><i>Background:</i></b> To evaluate the efficacy and safety of topical β-blockers in the treatment of superficial infantile hemangiomas (SIH) and mixed infantile hemangiomas (MIH), respectively, and compare the efficacy and safety of topical β-blockers with other interventions. <b><i>Methods:</i></b> The PRISMA guidelines were adhered to. We searched for randomized controlled trials in databases from 2010 to 2018 comparing topical β-blockers with other interventions for infantile hemangiomas. The outcomes evaluated were efficacy and adverse effects. Data analyses were performed using RevMan 5.3. Publication bias was assessed to account for bias in patient selection. <b><i>Results:</i></b> Eleven studies, involving 1,235 patients, were subjected to this meta-analysis. Six studies compared topical β-blockers with other interventions (propranolol, placebo, corticosteroids or pulsed dye laser) in treating SIH, and 5 studies evaluated the efficacy and safety of a topical β-blocker when it was combined with another intervention in treating MIH. A topical β-blocker was discovered to be as effective as oral propranolol in treating SIH (risk ratio, RR, 0.96, 95% confidence interval, CI, 0.91–1.02, <i>p</i> = 0.20, <i>I</i><sup>2</sup> = 0%), and topical β-blockers were more beneficial than placebo, corticosteroids or pulsed dye laser in treating SIH (RR 2.25, 95% CI 1.66–3.05, <i>p</i> &lt; 0.00001, <i>I</i><sup>2</sup> = 0%). Topical β-blockers combined with another intervention gave rise to a better clinical response in the treatment of MIH than intervention alone (RR 1.99, 95% CI 1.10–3.60, <i>p</i> = 0.02, <i>I</i><sup>2</sup> = 55%) (standard mean difference 0.80, 95% CI 0.28–1.31, <i>p</i> = 0.002, <i>I</i><sup>2</sup> = 0%). Compared with oral propranolol, topical β-blockers were associated with fewer incidences of adverse effects (RR 0.05, 95% CI 0.01–0.39, <i>p</i> = 0.004, <i>I</i><sup>2</sup> = 0%). No significant difference in adverse effects was found when a topical β-blocker was combined with another intervention in treating MIH (RR 1.01, 95% CI 0.58–1.74, <i>p</i> = 0.98, <i>I</i><sup>2</sup> = 0%). <b><i>Conclusions:</i></b> This meta-analysis provided evidence that topical β-blockers may replace oral propranolol as first-line therapy for SIH and that they are of additive value in treating MIH.
DOI: 10.6084/m9.figshare.13060556
title: Supplementary Material for: High Expression of MMP-9 in Primary Tumors and High Preoperative MPO in Serum Predict Improved Prognosis in Colorectal Cancer with Operable Liver Metastases

description: <b><i>Introduction:</i></b> The liver metastases of colorectal cancer (CRC) can be surgically treated in selected cases, with continuously improving results. Matrix metalloproteinases (MMPs) contribute to cancer invasion by degrading the extracellular matrix, and elevated levels of MMP-2, MMP-8, and MMP-9 have been detected in several malignancies. Myeloperoxidase (MPO) is a mediator of tissue damage that can oxidatively activate latent MMPs. We evaluated the prognostic value of MMP-2, MMP-8, and MMP-9 in tissue samples of primary tumors and liver metastases and the pre- and postoperative serum levels of MMP-8, MMP-9, and MPO in CRC patients undergoing liver resection. <b><i>Methods:</i></b> Tissue and serum samples were obtained from 111 patients who had primary colorectal tumors and their liver metastases surgically treated at the Helsinki University Hospital between 1988 and 2007. Tissue expression of MMP-2, MMP-8, and MMP-9 in primary tumors and liver metastases was evaluated by immunohistochemistry. Pre- and postoperative serum concentrations of MMP-8, MMP-9, and MPO were determined using a time-resolved immunofluorometric assay or commercially available enzyme-linked immunosorbent assay kits. Clinical data were retrieved from patient records and the Central Statistical Office of Finland. Associations with disease-free survival (DFS) and overall survival (OS) were estimated using Cox regression analysis and the Kaplan-Meier method. <b><i>Results:</i></b> High expression of MMP-9 in colorectal tumor tissue was associated with better DFS (<i>p</i> = 0.010), and high preoperative MPO in serum with improved DFS and OS (<i>p</i> &lt; 0.001 and <i>p</i> = 0.014, respectively). The prognostic significance varied according to gender, age, and the synchronicity of liver metastases. <b><i>Conclusion:</i></b> Low preoperative MPO in serum might identify patients at high risk of recurrence and death after resection of colorectal liver metastases. Elevated preoperative MPO and high expression of MMP-9 in colorectal tumor tissue indicate an improved prognosis. The use of these biomarkers should be adjusted according to clinical characteristics.
DOI: 10.25919/5f7d872e0cf4e
title: Parkes observations for project P1069 semester 2020APRS_06

description: We propose to carry out Parkes follow-up observations of pulsar candidates identified in the Rapid ASKAP Continuum Survey (RACS). This is the first all-sky pulsar survey in the imaging domain in the southern hemisphere thanks to ASKAP. Eight sources have been selected because of (1) their very high fraction of circular polarisation; (2) their lack of optical counterparts; (3) strong variability, which might indicate either strong interstellar scintillation or eclipsing by companion stars if in binaries; (4) the non-detection of these relatively bright sources in previous pulsar surveys, which might indicate extreme nature of these candidates. High time and frequency resolution targeted search with UWL are proposed. Such observations will enable us to carry out deep searches of pulsars with very short spin periods or in compact binaries.
DOI: 10.6084/m9.figshare.4516655
title: Circulating chromogranin B levels in patients with acute respiratory failure: data from the FINNALI Study

description: <b>Purpose:</b> Circulating chromogranin B (CgB) levels are increased in situations characterized by systemic and myocardial stress, but whether CgB provides prognostic information in patients with acute respiratory failure (ARF) is unknown. <b>Methods:</b> We included 584 patients with ARF, defined as ventilatory support &gt;6 h, and with blood samples available on Intensive Care Unit (ICU) admission and day 3 (<i>n</i> = 479). CgB levels were measured by radioimmunoassay and follow-up was 90 days. <b>Results:</b> One-hundred-sixty-nine patients (29%) died during follow-up. Admission CgB levels separated non-survivors from survivors: median 1234 (Q1-3 989–1742) vs. 917 (753–1224) pmol/L, respectively, <i>p</i> p <b>Conclusions:</b> CgB levels measured on ICU admission provided additional prognostic information to established risk indices in ARF patients.
DOI: 10.6084/m9.figshare.4516655.v1
title: Circulating chromogranin B levels in patients with acute respiratory failure: data from the FINNALI Study

description: <b>Purpose:</b> Circulating chromogranin B (CgB) levels are increased in situations characterized by systemic and myocardial stress, but whether CgB provides prognostic information in patients with acute respiratory failure (ARF) is unknown. <b>Methods:</b> We included 584 patients with ARF, defined as ventilatory support &gt;6 h, and with blood samples available on Intensive Care Unit (ICU) admission and day 3 (<i>n</i> = 479). CgB levels were measured by radioimmunoassay and follow-up was 90 days. <b>Results:</b> One-hundred-sixty-nine patients (29%) died during follow-up. Admission CgB levels separated non-survivors from survivors: median 1234 (Q1-3 989–1742) vs. 917 (753–1224) pmol/L, respectively, <i>p</i> p <b>Conclusions:</b> CgB levels measured on ICU admission provided additional prognostic information to established risk indices in ARF patients.
DOI: 10.6084/m9.figshare.5097217
title: Head-to-head comparison of cardiac troponin T and troponin I in patients without acute coronary syndrome: a systematic review

description: <b>Background:</b> Cardiac-specific troponin T (cTnT) and troponin I (cTnI) are considered diagnostically equal in patients with acute coronary syndrome (ACS). The aim of this systematic review was to compare the prevalence and prognostic strength of elevations of cTnT and cTnI in patients with other conditions than ACS. <b>Methods:</b> A systemic review was conducted in concordance with the PRISMA guidelines. The studies were identified by searching PubMed, EMBASE and Cochrane Central Register, from May to August 2016. Studies measuring both cTnT and cTnI in populations without ACS were eligible. <b>Results:</b> Twenty-nine studies were included (<i>n</i> = 25,859). Seventeen studies reported on prognostic information with follow-up time ranging for 30 d–5 years. Elevation above the 99th percentile (reference value for a healthy population) in non-ACS population was reported to be 0–39% for cTnI and 40–100% for cTnT. Elevation of cTnT tends to be a superior predictor for all-cause mortality and elevation of cTnI tends to be a superior predictor for cardiovascular related mortality. <b>Discussion:</b> In the absence of ACS, elevation of cTnT is more frequent than elevation of cTnI. <b>Conclusion:</b> Both cTnT and cTnI elevations have important prognostic information regarding morbidity, cardiac mortality and all-cause mortality.
DOI: 10.6084/m9.figshare.5097217.v1
title: Head-to-head comparison of cardiac troponin T and troponin I in patients without acute coronary syndrome: a systematic review

description: <b>Background:</b> Cardiac-specific troponin T (cTnT) and troponin I (cTnI) are considered diagnostically equal in patients with acute coronary syndrome (ACS). The aim of this systematic review was to compare the prevalence and prognostic strength of elevations of cTnT and cTnI in patients with other conditions than ACS. <b>Methods:</b> A systemic review was conducted in concordance with the PRISMA guidelines. The studies were identified by searching PubMed, EMBASE and Cochrane Central Register, from May to August 2016. Studies measuring both cTnT and cTnI in populations without ACS were eligible. <b>Results:</b> Twenty-nine studies were included (<i>n</i> = 25,859). Seventeen studies reported on prognostic information with follow-up time ranging for 30 d–5 years. Elevation above the 99th percentile (reference value for a healthy population) in non-ACS population was reported to be 0–39% for cTnI and 40–100% for cTnT. Elevation of cTnT tends to be a superior predictor for all-cause mortality and elevation of cTnI tends to be a superior predictor for cardiovascular related mortality. <b>Discussion:</b> In the absence of ACS, elevation of cTnT is more frequent than elevation of cTnI. <b>Conclusion:</b> Both cTnT and cTnI elevations have important prognostic information regarding morbidity, cardiac mortality and all-cause mortality.